Literature DB >> 16317525

Improvement in cardiac function of diabetic rats by bosentan is not associated with changes in the activation of PKC isoforms.

Jihong Jiang1, Violet Yuen, Hong Xiang, John H McNeill.   

Abstract

We previously demonstrated that chronic treatment with the mixed endothelin A and B (ET(A) and ET(B)) receptor blocker bosentan improved isolated working heart function in streptozotocin (STZ) diabetic rats. Endothelin-1 (ET-1) peptide levels, ET-1 mRNA and ET(A) and ET(B) receptor mRNA were all increased in diabetic hearts, but were unaffected by bosentan treatment, indicating that the beneficial effects of bosentan on heart appear to be on downstream effectors of ET-1 and ET receptors rather than the ET-1 system itself. Stimulation of ET-1 receptors leads to increased activation of protein kinase C (PKC), which is associated with PKC translocation from the cytosol to the membrane. Persistent activation of specific PKC isoforms has been proposed to contribute to diabetic cardiomyopathy. The purpose of this study was to determine whether chronic treatment with bosentan influences the activation of PKC isoforms in hearts from diabetic rats. Male Wistar rats were divided into four groups: control, bosentan-treated control, diabetic, and bosentan-treated diabetic. Diabetes was induced by the intravenous injection of 60 mg/kg streptozotocin. One week later, treatment with bosentan (100 mg/kg/day) by oral gavage was begun and continued for 10 weeks. The heart was then removed, homogenized, separated into soluble (cytosolic) and particulate (membrane) fractions and PKC isoform content in each fraction was determined by Western blotting. PKC alpha, beta2, delta, epsilon and zeta were all detected in hearts from both control and diabetic rats. However, no change in the levels or distribution between the soluble and particulate fractions of any of these isoforms could be detected in chronic diabetic hearts compared to control, whether untreated or treated with bosentan. These observations indicate that bosentan does not improve cardiac performance in STZ diabetic rats by affecting the activation of PKC isoforms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16317525     DOI: 10.1007/s11010-006-1926-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.842


  53 in total

Review 1.  Signal transduction in cardiac hypertrophy--dissecting compensatory versus pathological pathways utilizing a transgenic approach.

Authors:  Y Wang
Journal:  Curr Opin Pharmacol       Date:  2001-04       Impact factor: 5.547

Review 2.  Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C.

Authors:  Y Nishizuka
Journal:  Science       Date:  1992-10-23       Impact factor: 47.728

Review 3.  Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes.

Authors:  I Idris; S Gray; R Donnelly
Journal:  Diabetologia       Date:  2001-06       Impact factor: 10.122

4.  Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy.

Authors:  H Wakasaki; D Koya; F J Schoen; M R Jirousek; D K Ways; B D Hoit; R A Walsh; G L King
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

5.  Increased expression of Galphaq protein in the heart of streptozotocin-induced diabetic rats.

Authors:  J M Yang; C H Cho; K A Kong; I S Jang; H W Kim; Y S Juhnn
Journal:  Exp Mol Med       Date:  1999-12-31       Impact factor: 8.718

6.  Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes.

Authors:  A Benigni; V Colosio; C Brena; I Bruzzi; T Bertani; G Remuzzi
Journal:  Diabetes       Date:  1998-03       Impact factor: 9.461

7.  Exaggerated coronary reactivity to endothelin-1 in diabetes: reversal with bosentan.

Authors:  Subodh Verma; Emi Arikawa; Sammy Lee; Aaron S Dumont; Linfu Yao; John H McNeill
Journal:  Can J Physiol Pharmacol       Date:  2002-10       Impact factor: 2.273

8.  Differential effects of endothelin-1 on basal and isoprenaline-enhanced Ca2+ current in guinea-pig ventricular myocytes.

Authors:  G P Thomas; S M Sims; M Karmazyn
Journal:  J Physiol       Date:  1997-08-15       Impact factor: 5.182

9.  Protein kinase C activation contributes to microvascular barrier dysfunction in the heart at early stages of diabetes.

Authors:  S Y Yuan; E E Ustinova; M H Wu; J H Tinsley; W Xu; F L Korompai; A C Taulman
Journal:  Circ Res       Date:  2000-09-01       Impact factor: 17.367

10.  Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents.

Authors:  K Ono; G Tsujimoto; A Sakamoto; K Eto; T Masaki; Y Ozaki; M Satake
Journal:  Nature       Date:  1994-07-28       Impact factor: 49.962

View more
  4 in total

1.  The lung endothelin system: a potent therapeutic target with bosentan for the amelioration of lung alterations in a rat model of diabetes mellitus.

Authors:  A Cayir; R A Ugan; A Albayrak; D Kose; E Akpinar; Y Cayir; H T Atmaca; Z Bayraktutan; M Kara
Journal:  J Endocrinol Invest       Date:  2015-04-07       Impact factor: 4.256

2.  Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension.

Authors:  Gaurav Choudhary; Frederick Troncales; Douglas Martin; Elizabeth O Harrington; James R Klinger
Journal:  J Heart Lung Transplant       Date:  2011-05-08       Impact factor: 10.247

3.  Exercise-induced cardiac performance in autoimmune (type 1) diabetes is associated with a decrease in myocardial diacylglycerol.

Authors:  Rajprasad Loganathan; Lesya Novikova; Igor G Boulatnikov; Irina V Smirnova
Journal:  J Appl Physiol (1985)       Date:  2012-07-12

4.  Differential expression of protein kinase C isoforms in coronary arteries of diabetic mice lacking the G-protein Gα11.

Authors:  Dieter Paul Hoyer; Yüksel Korkmaz; Sabine Grönke; Klaus Addicks; Nina Wettschureck; Stefan Offermanns; Hannes Reuter
Journal:  Cardiovasc Diabetol       Date:  2010-12-29       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.